COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,358 Articles (22,803 medRxiv, 8,555 bioRxiv)

Most recent first Previous |  Page 1456: Articles 14551-14560  | Next

Post-Infection Entry Mechanism of Ricin A Chain-Pokeweed Antiviral Proteins (RTA-PAPs) Chimeras is Mediated by Viroporins
Hassan, Y.
10.1101/2021.06.17.448882 — Posted: 2021-06-17
Western diet increases COVID-19 disease severity in the Syrian hamster
Port, J. R., Adney, D. R., Schwarz, B., Schulz, J., Sturdevant, D. E., Smith, B. J., Avanzato, V., Holbrook, M. G., Purushotham, J., Stromberg, K. A., Leighton, I., Bosio, C., Shaia, C., Munster, V.
10.1101/2021.06.17.448814 — Posted: 2021-06-17
Specificity and Mechanism of Coronavirus, Rotavirus and Mammalian Two-Histidine-Phosphoesterases That Antagonize Antiviral Innate Immunity
Asthana, A., Gaughan, C., Weiss, S. R., Silverman, R. H.
10.1101/2021.06.16.448777 — Posted: 2021-06-17
A stem-loop RNA RIG-I agonist confers prophylactic and therapeutic protection against acute and chronic SARS-CoV-2 infection in mice
Mao, T., Israelow, B., Lucas, C., Vogels, C. B. F., Fedorova, O., Breban, M. I., Menasche, B. L., Dong, H., Linehan, M., Yale SARS-CoV-2 Genome Surveillance Initiative, , Wilen, C. B., Landry, M. L., Grubaugh, N. D., Pyle, A. M., Iwasaki, A.
10.1101/2021.06.16.448754 — Posted: 2021-06-17
Designing a Novel Multi-Epitope Vaccine against SARS-CoV-2; Implication for Viral Binds and Fusion Inhibition through Inducing Neutralizing Antibodies
Mohammadzadeh Hosseini Moghri, S. A. H., Ranjbar, M., Hassannia, H., Khakdan, F.
10.1101/2021.06.16.448772 — Posted: 2021-06-17
Coadministration of AYUSH 64 as an adjunct to Standard of Care in mild and moderate COVID-19: A randomised, controlled, multicentric clinical trial
Chopra, A., Tillu, G., Chaudhary, K., Reddy, G., Srivastava, A., Lakdawala, M., Gode, D., Reddy, H., Tamboli, S., Saluja, M., Sarmukkaddam, S., Gundeti, M., Raut, A., Rao, B., Yadav, B., Srikanth, N., Patwardhan, B.
10.1101/2021.06.12.21258345 — Posted: 2021-06-17
Ceylon cinnamon and its major compound Cinnamaldehyde can limit overshooting inflammatory signaling and angiogenesis in vitro: implications for COVID-19 treatment
Lucas, K., Ackermann, M., Leifke, A. L., Li, W. W., Poeschl, U., Froehlich-Nowoisky, J.
10.1101/2021.06.16.448642 — Posted: 2021-06-16
Nafamostat-interferon-alpha combination suppresses SARS-CoV-2 infection in vitro and in vivo
Ianevski, A., Yo, R., Lysvand, H., Grodeland, G., Legrand, N., Tenson, T., Bjoras, M., Kainov, D. E.
10.1101/2021.06.16.448653 — Posted: 2021-06-16
A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters
Wuertz, K. M., Barkei, E., Chen, W.-h., Martinez, E. J., Naouar, I. E., Jagodzinski, L., Paquin-Proulx, D., Gromowski, G. D., Swafford, I., Ganesh, A., Dong, M., Zeng, X., Thomas, P. V., Sankhala, R. S., Hajduczki, A., Peterson, C. E., Kuklis, C. H., Soman, S., Wieczorek, L., Zemil, M., Anderson, A., Darden, J., Hernandez, H., Grove, H., Dussupt, V., Hack, H., de la Barrera, R. A., Zarling, S. N., Wood, J. F., Froude, J. W., Gagne, M. J., Henry, A. R., Mokhtari, E. B., Mudvari, P., Krebs, S. J., Pekosz, A. S., Currier, J. R., Kar, S., Porto, M., Winn, A., Radzyminski, K., Lewis, M. G., Vasan, S., Suthar, M., Polonis, V., Matyas, G., Boritz, E. A., Douek, D. C., Seder, R., Daye, S., Rao, M., Peel, S., Joyce, M. G., Bolton, D. L., Michael, N. L., Modjarrad, K.
10.1101/2021.06.16.448525 — Posted: 2021-06-16
SARS-CoV-2 envelope-protein corruption of homeostatic signaling mechanisms in mammalian cells
Schulze, T., Hartel, A., Hoeler, S., Hemming, C., Lehn, R., Tandl, D., Greiner, T., Bertl, A., Shepard, K., Moroni, A., Thiel, G., Rauh, O.
10.1101/2021.06.16.448640 — Posted: 2021-06-16

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).